A Phase 2 Basket Study of Vosoritide in Children With Turner Syndrome, SHOX Deficiency and Noonan Syndrome With an Inadequate Response to Human Growth Hormone

Last updated: May 8, 2025
Sponsor: BioMarin Pharmaceutical
Overall Status: Active - Recruiting

Phase

2

Condition

Turner Syndrome

Hypogonadism

Severe Short Stature

Treatment

Human Growth Hormone

Vosoritide Injection

Clinical Study ID

NCT06668805
111-211
  • Ages 3-11
  • All Genders

Study Summary

The purpose of this basket study in children with Turner syndrome, SHOX deficiency, and Noonan syndrome is to evaluate the effect of 3 doses of vosoritide versus hGH on growth as measured by AGV after 6 months of treatment. The long-term efficacy and safety of vosoritide at the therapeutic dose will be evaluated up to FAH.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  1. Participants must be ≥ 3 years old, and < 10 years old (females) or < 11 years old (males),at the time of signing the informed consent form

  2. A genetically confirmed diagnosis of Turner syndrome, SHOX deficiency or Noonansyndrome.

  3. A height assessment corresponding to a height Z score of ≤ -2.00 SDs in reference tothe general population of the same age and sex.

  4. Tanner Stage 1, at time of signing the ICF.

  5. Have been receiving continuous hGH for the treatment of short stature associatedwith their condition for a minimum of 1 year immediately prior to enrollment.

  6. Are willing to continue on hGH for the Baseline Growth Phase, and for 2 years postrandomization if randomized to the hGH arm.

  7. Inadequate response to prior hGH treatment.

Exclusion

Exclusion Criteria:

  1. Participants with Turner syndrome known to have Y-chromosome material unless theyhave undergone gonadectomy and have fully external female genitalia.

  2. Diagnosis of systemic disease or condition that may cause short stature other thanTurner syndrome, SHOX deficiency, or Noonan syndrome, eg, renal, neoplastic,pulmonary, cardiac, gastrointestinal, immunologic and metabolic disease.

  3. Bone age advanced beyond chronological age by more than 2 years.

  4. Congenital heart disease which places the participant at increased risk of anadverse cardiac outcome in the setting of hypotension,

  5. Have an unstable condition likely to require surgical intervention during the study.

  6. Evidence of decreased growth velocity (AGV < 1.5 cm/year) as assessed over a periodof at least 6 months and growth plate closure assessed using bilateral lowerextremity X-rays.

  7. Previous limb-lengthening surgery, or planned or expected to have limb lengtheningsurgery during the study period.

  8. Planned or expected bone-related surgery (ie, surgery involving disruption of bonecortex, excluding tooth extraction), during the study period.

Study Design

Total Participants: 72
Treatment Group(s): 2
Primary Treatment: Human Growth Hormone
Phase: 2
Study Start date:
November 22, 2024
Estimated Completion Date:
September 30, 2041

Study Description

This is a Phase 2, randomized, active-controlled, multicenter, basket study of vosoritide in children with Turner syndrome, short stature homeobox-containing gene (SHOX) deficiency, or Noonan syndrome who have an inadequate response to human growth hormone (hGH) treatment. The study is intended to characterize the short-term efficacy and safety of 3 dosing regimens of vosoritide versus hGH. The efficacy and safety of the vosoritide therapeutic dose will be further evaluated, with a comparison to hGH after 2 years of treatment, and an analysis of the impact of vosoritide on final adult height (FAH).

Connect with a study center

  • Angers University Hospital Center

    Angers, Maine-et-Loire 49 933
    France

    Active - Recruiting

  • CHU de Toulouse - Hôpital des Enfants

    Toulouse, Occitanie
    France

    Active - Recruiting

  • Central University Hospital of Asturias

    Oviedo, Asturias 33011
    Spain

    Site Not Available

  • Children's Hospital Colorado

    Aurora, Colorado 80045
    United States

    Active - Recruiting

  • Nemours Children's Hospital, Delaware (Alfred I. Dupont Hospital for Children)

    Wilmington, Delaware 19803
    United States

    Active - Recruiting

  • Nicklaus Children's Hospital

    Miami, Florida 33155
    United States

    Site Not Available

  • St. Luke's Children's Endocrinology and Diabetes

    Boise, Idaho 83712
    United States

    Active - Recruiting

  • Kentucky Children's Hospital

    Lexington, Kentucky 40506
    United States

    Active - Recruiting

  • New York Medical College

    Boston, Massachusetts 02115
    United States

    Active - Recruiting

  • M Health Fairview Pediatric Specialty Clinic - Explorer

    Minneapolis, Minnesota 55454
    United States

    Active - Recruiting

  • Children's Hospital at Montefiore

    Bronx, New York 10467
    United States

    Active - Recruiting

  • Atrium Health Carolinas Medical Center

    Charlotte, North Carolina 28203
    United States

    Active - Recruiting

  • University of Texas Health Science Center at Houston (UT Health)

    Houston, Texas 77030
    United States

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.